Company performance
Add to research
Current Price
as of Feb 14, 2025$2.56
P/E Ratio
N/A
Market Cap
$1.55B
Description
Add to research
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
Metrics
Add to research
Overview
- HQFoster City, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerGERN
- Price$2.56-8.24%
Trading Information
- Market cap$1.55B
- Float93.39%
- Average Daily Volume (1m)11,278,048
- Average Daily Volume (3m)10,969,089
- EPS-$0.32
Company
- Revenue$29.48M
- Rev growth (1yr)17,138.41%
- Net income-$26.45M
- Gross margin97.68%
- EBITDA margin-99.09%
- EBITDA-$28.01M
- EV$2.75B
- EV/Revenue93.35
- P/EN/A
- P/S57.50
- P/B5.28
- Debt/Equity29.86
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account